Stocks · News reference

Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

Aug 14, 2026, 2:59 PMBenzinga Newsdesk

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 9, 2026, 11:08 AMBenzinga Newsdesk
Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
FATE
BenzingaAug 14, 2026, 4:31 PMBenzinga Newsdesk
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8
Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.
FATE
BenzingaAug 14, 2026, 1:10 PMBenzinga Newsdesk
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
FATE